Whoop MG Device CEO Will Ahmed Defies FDA, Keeps Blood Pressure Tracking for Wellness Use

Whoop, the maker of screen-less fitness bands, has refused to disable its Blood Pressure Insights feature following a warning letter from the US Food and Drug Administration (FDA) issued last month. The FDA's letter stated that the feature causes the device to be classified as a medical device, which would subject it to regulatory oversight. Whoop's CEO, Will Ahmed, emphasized that the blood pressure tracking tool is intended solely for wellness use and confirmed the company's decision to keep the feature active. Whoop has expressed willingness to engage in dialogue with the FDA but remains confident in its position. The dispute centers around the company's new Whoop MG device. Meanwhile, Apple has reportedly found a way to reintroduce blood oxygen monitoring to some Apple Watch models in the US despite regulatory challenges.